1. Alzheimer’s Association International Conference. BAN2401 Phase 2 Data released at AAIC 2018. July 22-26, 2018, Chicago, ILL. https://www.alz.org/aaic/releases_2018/AAIC18-Wed-3-30-pm.asp
2. Eisai Global. Eisai and biogen announce detailed results of phase II clinical study of BAN2401 in early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018. July 25, 2018.
3. Swanson CJ, Zhang Y, Dhadda S, et al. Treatment of Early AD subjects with BAN2401, an Anti-Aβ Protofibril Monoclonal Antibody, Significantly Clears Amyloid Plaque and Reduces Clinical Decline. Abstract 27531.